Active — Not RecruitingPhase 4

DOMPE -MT Neurotrophic Keratitis

United States10 participantsStarted 2023-01-21

Plain-language summary

TITLE: Toyos Clinic / A Phase 4 Study to Assess Longer Duration of Treatment with Cenegermin in Moderate to Severe Dry Eye-Associated Neurotrophic Keratitis

Who can participate

Age range18 Years – 85 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. Have a known hypersensitivity or contraindication to the investigational product or their components.
✕. Severe systemic allergy.
✕. Topical glaucoma medications or oral medications that are not being taken at a stable dose for the past 90 days.
✕. Topical dry eye medications within the last month except unpreserved artificial tears which will be allowed throughout the study as needed.
✕. Active viral, fungal or bacterial infection or active intraocular inflammation.
✕. Subjects must be unwilling to abstain from eyelash growth medications for the duration of the trial.
✕. Subjects must not have had penetrating intraocular surgery, refractive surgery or corneal transplantation, eyelid surgery within 12 weeks prior to Visit 1.
✕. Febrile illness within one week of screening visit.

What they're measuring

TITLE: Toyos Clinic / A Phase 4 Study to Assess Longer Duration of Treatment with Cenegermin in Moderate to Severe Dry Eye-Associated Neurotrophic Keratitis

Timeframe: 8 months

Trial details

NCT IDNCT06947850

SponsorToyos Clinic

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-09-25

View on ClinicalTrials.gov More Dry Eye trials